Effect of Prostatan on symptoms of patients with benign prostatic hyperplasia

Effect of the herbal medicine Prostatan® on lower urinary tract symptoms severity of patients with benign prostatic hyperplasia: A randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150420021869N6

Enrollment

Registered

2023-05-14

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: Prostatan drug (GOLDAROU company Isfahan_Iran) will be prescribed in this group. dosage will be 1 pill every 12 hours for 3 months. Intervention 2: Control group: I

Eligibility

Sex/Gender

Male

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed with benign prostatic hyperplasia based on clinical diagnosis Moderate lower urinary tract symptoms due to IPSS score Age more than 40 years old

Exclusion criteria

Exclusion criteria: Not having consent to enter the study Patients having lower urinary tract symptoms due to other causes including ureteral stricture, prostate cancer, bladder neck cancer, bladder or ureteral stone, neurogenic bladder, or urinary tract infection Patients with liver or kidney failure

Design outcomes

Primary

Measure	Time frame
IPSS score. Timepoint: At baseline and 3 months after intervention. Method of measurement: IPSS questionnaire.	—

Secondary

Measure	Time frame
Serum PSA level. Timepoint: At baseline and 3 months after intervention. Method of measurement: Blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad Gholipour

Esfahan University of Medical Sciences

farshad.gholipoor@gmail.com+98 31 3669 7898

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026